In patients with HCV-related cirrhosis the annual risk of hepatocellular carcinoma (HCC) is 2–4%.1 However, with the advent of highly effective and well tolerated direct-acting antivirals...

Calvaruso V., & Bruix J. (2020). Towards personalized screening for hepatocellular carcinoma: Still not there [10.1016/j.jhep.2020.06.032].

Towards personalized screening for hepatocellular carcinoma: Still not there

Calvaruso V.
;
2020

Abstract

In patients with HCV-related cirrhosis the annual risk of hepatocellular carcinoma (HCC) is 2–4%.1 However, with the advent of highly effective and well tolerated direct-acting antivirals...
Calvaruso V., & Bruix J. (2020). Towards personalized screening for hepatocellular carcinoma: Still not there [10.1016/j.jhep.2020.06.032].
File in questo prodotto:
File Dimensione Formato  
Towards personalized screening for hepatocellular carcinoma- still not there.pdf

Solo gestori archvio

Tipologia: Versione Editoriale
Dimensione 360.64 kB
Formato Adobe PDF
360.64 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/509955
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact